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Amplification of the 11q13 region is one of the most frequent aberrations in squamous cell carcinomas of the head and neck region
(HNSCC). Amplification of 11q13 has been shown to correlate with the presence of lymph node metastases and decreased survival.
The 11q13.3 amplicon carries numerous genes including cyclin D1 and cortactin. Recently, we reported that FADD becomes
overexpressed upon amplification and that FADD protein expression predicts for lymph node positivity and disease-specific
mortality. However, the gene within the 11q13.3 amplicon responsible for this correlation is yet to be identified. In this paper, we
compared, using immunohistochemical analysis for cyclin D1, FADD and cortactin in a series of 106 laryngeal carcinomas which gene
correlates best with lymph node metastases and increased disease-specific mortality. Univariate Cox regression analysis revealed that
high expression of cyclin D1 (P¼0.016), FADD (P¼0.003) and cortactin (P¼0.0006) predict for increased risk to disease-specific
mortality. Multivariate Cox analysis revealed that only high cortactin expression correlates with disease-specific mortality independent
of cyclin D1 and/or FADD. Of genes located in the 11q13 amplicon, cortactin expression is the best predictor for shorter disease-
specific survival in late stage laryngeal carcinomas.
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Current methods to predict the outcome of head and neck
squamous cell carcinoma (HNSCC) patients mainly involve
clinicopathological parameters such as tumour size, differentiation
grade and presence of lymph node metastasis. Patients with
laryngeal squamous cell carcinomas (LSCC) have not shown an
increase in 5-year survival rates over the last 30 years (Almadori
et al, 2005). Therefore, other parameters such as molecular
markers that are able to more accurately predict the outcome of
disease, are needed.
A frequent molecular event in HNSCC is amplification of the
11q13 region (36%) (Schuuring, 1995; Freier et al,2 0 0 6 ) .
Amplification of this region in HNSCC has been associated with
decreased survival (Akervall et al, 1995; Meredith et al, 1995),
increased distant metastasis (Namazie et al, 2002) and lymph node
metastasis (Chen et al, 2004; Hermsen et al,2 0 0 5 ;X i aet al,2 0 0 7 ) .I t
is believed that amplification increases gene dosage and expression
of genes within the amplified region (amplicon) (Albertson, 2006).
Recently, we reported that the commonly amplified region is located
at 11q13.3 and contains at least six genes (cyclin D1, TAOS1, FGF19,
FADD, PPFIA1 and cortactin) that are overexpressed when
amplified (Gibcus et al, 2007b). We concluded that the selection
for tumour cells with the 11q13.3 amplicon during tumorigenesis
could be based on the increased doses of one or more of these genes.
We proposed FADD as a possible candidate for this selection, since
FADD showed the best correlation between DNA amplification and
increased expression (Gibcus et al, 2007b). Furthermore, FADD
protein expression correlated with disease specific mortality (DSM)
in a series of late stage laryngeal carcinomas. FADD protein
expression was independent of lymph node metastasis and patients
with both high FADD protein expression and lymph node
metastasis had the worst prognosis for survival (Gibcus et al,
2007b). However, although FADD is a prognostic marker for
increased mortality, we can not exclude that other genes within the
11q13 region are (also) involved.
The most frequently studied genes within the 11q13.3 region are
cyclin D1 and cortactin (Schuuring, 1995). Overexpression of
cyclin D1 at both protein and RNA level have been linked to poor
prognosis in numerous studies (Akervall et al, 1997; Yu et al, 2005;
Higuchi et al, 2007). Cortactin amplification was related to
increased lymph node stage, advanced disease stage and reduced
survival (Rodrigo et al, 2000). Cortactin mRNA expression (Luo
et al, 2006) and protein expression (Rothschild et al, 2006) have
been correlated to increased lymph node metastasis.
In summary, FADD, cyclin D1 and cortactin expression may
each be involved in processes resulting in increased lymph node
metastasis and in poor prognosis. Because the prognostic value of
these genes has not been evaluated within the same group of
patients simultaneously, we have performed immunohistochem-
istry (IHC) on 167 patients with late stage LSCC. Since lymph node
metastases have been shown to be an important prognostic factor
for DSM, we assessed the additional prognostic value of cyclin D1,
FADD and cortactin in late stage LSCC.
MATERIALS AND METHODS
Patient inclusion
For immunohistochemical analysis we selected 167 patients
diagnosed with a squamous cell carcinoma of the larynx,
previously used for IHC of FADD. Patient material and available
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Medical Center Groningen (n¼56), The Netherlands Cancer
Institute–Antoni Van Leeuwenhoek Hospital (n¼62), the In-
stituto Universitario de Oncologı ´a del Principado de Asturias
(n¼22) and the Leiden University Medical Center, Leiden, the
Netherlands (n¼28). Successful staining for all three antibodies
was examined on 120 patients. Sufficient follow-up was available
for 106 of 120 patients. In the other 61 cases follow-up was short or
unavailable, material was lost in the IHC-process or, no or too few
tumour cells were present in the tissue block. The remaining
patient group (n¼106) consisted mainly of larger tumours: T1
(n¼8; 8%), T2 (n¼22; 21%), T3 (n¼31; 29%) and T4 (n¼45;
42%) that were either treated with surgery, radiotherapy or a
combination of both treatments. Patients who did not die had a
median follow-up of 72 months, whereas patients who died had a
median follow-up of 16 months. The clinical characteristics of the
106 cases were comparable to the characteristics of the total group
of 167 patients (see Table 1).
Immunohistochemistry
Immunohistochemistry for cyclin D1 was performed as previously
described (de Boer et al, 1995; Takes et al, 1998). For the
immunostaining of cortactin we used a commercially available
antibody (clone 30/cortactin from BD Transduction Laboratories,
Franklin Lakes, NJ, USA) that recognizes all cortactin isoforms and
can be applied on archival material. IHC for FADD on the larger
series of 167 LSCC was reported earlier (Gibcus et al, 2007b). Ki67
expression was used as a marker for cell proliferation. Paraffin-
embedded, formalin-fixed sections of laryngeal carcinoma were
deparaffinized and antigen retrieval was performed by overnight
incubation at 801C in Tris–HCL pH¼9.0 for Ki-67 and FADD,
or heating in a microwave oven for 15min in EDTA pH¼6.0 for
cortactin, or heating in a microwave oven in Tris–HCL pH¼9.0
for 30min for cyclin D1. After blocking endogenous peroxidases
with 0.3% H2O2, the sections were stained for 1h with an antibody
against cyclin D1 (sp4, 1:50, Abcam, Cambridge, UK), FADD
(1:100, BD Transduction Laboratories), cortactin (clone 30/
cortactin; 1:1000, BD Transduction Laboratories) and Ki-67
(MIB-1, 1:350; DAKO, Heverlee, Belgium). Secondary and tertiary
antibodies were diluted 1:100 in 1% BSA-PBS complemented with
1% AB-serum or EnVision (DAKO). Antibodies were precipitated
using 3, 30 diaminobenzidine tetrachloride as a substrate and the
slides were counterstained using routine haematoxylin treatment.
In parallel, a haematoxylin and eosin stained slide was scored by a
pathologist (JEvdW) to verify tumour content.
Scoring of the immunohistochemical staining of Cyclin D1 and
ki-67 was based on the percentage of positive tumour cells as
reported previously. Scoring for cortactin was also based on the
percentage of cells with high cytoplasmic expression. Expression
levels similar or lower than the intensity in the surrounding
normal tissue (used as the internal reference for staining) were
considered as low cortactin expressors and those with increased
intensity as high expressors. The intermingled lymphocytes served
as a negative control. For FADD the intensity of the positively
stained tumour cells was scored and divided into two different
categories; low expressors ( , þ) and high expressors (þþ,
þþþ) as described previously (Gibcus et al, 2007b).
Antibodies against PPFIA1 (LIP.1) (Serra-Pages et al, 1995) and
FGF19 (mab969; R&D Systems, Minneapolis, USA) appeared to be
inappropriate for IHC analysis (data not shown) and antibodies
against FLJ42258 and TAOS1 are presently not available.
Statistical analysis
Statistical analysis was performed using version 14.0 of the SPSS
software package. Cutoff percentages for dichotomization of the
data were determined for cyclin D1 and cortactin using the median
percentage of stained cells; 23% for nuclear cyclin D1 and 13% for
cytoplasmic cortactin staining (Table 1). Associations between IHC
staining patterns were identified by logistic regression. Prognostic
value was evaluated per staining using Kaplan–Meier curves and
univariate Cox regression for DSM to discern between deaths
without evidence of disease and death of disease. A multivariate
Cox regression model including cyclin D1, FADD, cortactin and
lymph node status and treatment were based on univariate
significance. All tests were two-sided and P-values of o0.05 were
considered significant.
RESULTS
To study which gene within the 11q13. 3 region is responsible for
the clinical outcome, we evaluated the expression of cyclin D1,
FADD and cortactin using a series of 106 LSSCs previously stained
for FADD expression (Table 1 and Figure 1). The other four
Table 1 Patient characteristics as determined for the entire series of 167
patients (series) and the overlapping group of 106 patients (overlap)
Characteristic Series (%) Overlap (%)
Age 155 106
Median 61 61
Range 34–89 34–89
o61 75 (48) 53 (50)
4¼61 80 (52) 53 (50)
Gender 156 106
Male 136 (87) 91 (86)
Female 20 (13) 15 (14)
T-status 167 106
T1 22 (13) 8 (8)
T2 29 (17) 22 (21)
T3 40 (24) 31 (29)
T4 76 (46) 45 (42)
Lymph nodes (cN) 166 106
N0 102 (61) 67 (63)
N1 24 (15) 16 (15)
N2 35 (21) 21 (20)
N3 5 (3) 2 (2)
Negative (N ) 102 (61) 67 (63)
Positive (N+) 64 (39) 39 (37)
Grade 156 106
Well 37 (24) 25 (24)
Moderate 79 (51) 51 (48)
Poor 40 (26) 30 (27)
Therapy 143 106
Surgery 55 (38) 42 (40)
RT 24 (17) 16 (15)
Surgery + RT 64 (45) 48 (45)
CCND1 138 106
Median percentage 20% 23%
o23% 71 (51) 52 (49)
423% 67 (49) 54 (51)
CTTN 136 106
Median percentage 10% 13%
o13% 71 (52) 55 (52)
413% 65 (48) 51 (48)
FADD 140 106
 /+ 78 (56) 60 (57)
++/+++ 62 (44) 46 (43)
Abbreviation: RT¼radiotherapy.
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et al, 2007b) were not investigated further because no antibodies
were available (TAOS1 and FLJ42258) or appeared to be
inappropriate for immunohistochemistry on archive material
(PPFIA1 and FGF19) (data not shown). Firstly, we determined
whether there was a link between amplification and protein
expression. For this purpose we immunostained a subset of 16
cases in which amplification was determined previously (Gibcus
et al, 2007a). Carcinomas with 11q13 amplification showed high
protein expression levels in 8/8 cases for cyclin D1, 8/9 cases for
FADD and 8/9 for cortactin (Table 2). In addition, the high
expression of cyclin D1 and cortactin in 5/8 and 3/7 cases without
amplification, respectively, and FADD only in 1/7 suggest that
FADD correlates best with amplification (Table 2). The frequencies
of high expression without amplification indicate that increased
expression of cyclin D1 and cortactin are caused by mechanisms
other than amplification.
Secondly, we evaluated whether protein expression of FADD,
cyclin D1 and cortactin (Figure 1) were related to increased DSM
and lymph node metastasis. Logistic regression for expression of
FADD, cyclin D1 and cortactin was performed on dichotomized
groups. The resulting odds ratios (OR) implicated that cortactin
positivity (OR¼11.2; 95% CI, 4.6–27.1) and cyclin D1 positivity
(OR¼3.82; 95% CI, 1.7–8.4) were related to FADD expression
(data not shown). The relation between protein expression and
increased DSM was determined using univariate Cox regression.
High expression of FADD, cyclin D1 and cortactin was related to
increased DSM (Table 3). Furthermore, lymph node metastasis, a
marker for worse prognosis, was also related to increased DSM,
whereas age, gender and tumour size were not. Treatment was also
related to increased DSM. However, the choice of treatment is
based on the prognosis obtained by classical prognostic factors
(such as lymph node metastasis). Cell division rates, determined
by immunohistochemical staining for Ki-67 levels (Figure 1D and
H), were not correlated to increased DSM in univariate Cox
regression. Although lymph node metastasis has been reported as
an important clinical prognosticator (Eiband et al, 1989; Gaspar-
otto and Maestro, 2007), cortactin expression (HR¼13.14; 95% CI,
3.04–56.87; P¼0.0006) correlated stronger to increased DSM than
lymph node metastasis (HR¼3.16; 95% CI, 1.29–7.75; P¼0.012)
(Table 3).
A multivariate Cox regression model including cortactin, cyclin
D1, FADD, treatment and lymph node metastasis showed that
cortactin expression (HR¼8.46; 95% CI, 1.63–43.88; P¼0.011)
and lymph node metastasis (HR¼3.96; 95% CI, 1.30–12.06;
P¼0.015) were predictors for increased DSM, whereas FADD and
cyclin D1 were not (Table 4A). Furthermore, in the multivariate
analysis treatment with surgery, radiotherapy or a combination
of both was not related to increased DSM (Table 4A). To assess
whether cortactin and lymph node metastasis were independent
prognostic factors, a multivariate Cox regression, using only
cortactin expression and lymph node metastasis, was performed.
Both cortactin expression and lymph node metastasis were
significantly related to increased DSM (Table 4B), implying they
are both prognostic factors. However, Kaplan–Meier analysis for
cortactin, within lymph node positive tumours only, revealed a
remarkable difference (Log-rank: P¼0.00002) in DSM between
cortactin-positive and cortactin-negative cases (Figure 2).
DISCUSSION
Cortactin predicts poor survival in late stage laryngeal
carcinomas
Amplification of the 11q13.3 region has been related to a worse
prognosis (Meredith et al, 1995; Xie et al, 2006). Furthermore,
expression of cortactin, cyclin D1 and more recently FADD
(Gibcus et al, 2007b), have been described separately as potential
predictors for increased disease-related mortality, for lymph node
metastasis and poor prognosis. Yet, the effect of overexpression
due to amplification in head and neck carcinomas have not been
examined for these proteins within the same group of patients.
A BCD
E F G H
Figure 1 Immunohistochemical staining for cyclin D1, cortactin and FADD. A case without amplification and low cyclin D1 (A), FADD (B) and cortactin
(C) expression and a case with amplification and high expression of cyclin D1 (E), FADD (F) and cortactin (G). Expression of ki-67 was unrelated to
expression of the 11q13.3 genes (D, H).
Table 2 Cross table showing the relation between amplification and
immunohistochemical staining for cyclin D1, FADD and cortactin
Immunohistochemistry
Negative Positive Total
CCND1 amplification
Negative 3 5 8
Positive 0 8 8
FADD amplification
Negative 6 1 7
Positive 1 8 9
CTTN amplification
Negative 4 3 7
Positive 1 8 9
Pearson w
2 P-values for cyclin D1, FADD and cortactin were 0.055, 0.003 and 0.049
respectively.
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good predictors for DSM using a multivariate model independent
of cyclin D1 and FADD (Table 4A). This implies a correlation
between lymph node metastasis and cortactin, as suggested
previously (Rothschild et al, 2006). However, also within the
lymph node metastasis positive group, high cortactin expression
identifies patients with significantly increased DSM, whereas low
cortactin expression identifies a group of patients with a good
prognosis for survival. These data indicate that cortactin
expression is independent of lymph node metastasis (Figure 2).
Cortactin, a regulator of ARP2/3-mediated actin polymerization,
is known to contribute to tumour cell growth and cancer
progression (Weed and Parsons, 2001). Downregulation of
cortactin in cancer cell lines decreases the cellular motility and
ability to migrate (Rothschild et al, 2006; van Rossum et al, 2006)
whereas overexpression resulted in an increased invasive potential
(van Rossum et al, 2003; Rothschild et al, 2006). In addition to the
effect on cell migration by mediating actin polymerization and cell
adhesion (van Rossum et al, 2006), cortactin might also influence
cell migration and metastasis by anoikis resistance and PI3K/Akt
signalling (Luo et al, 2006; Luo and Wang, 2007). Because of these
biological functions and its overexpression due to DNA amplifica-
tion, cortactin is the most likely gene within the 11q13.3 amplicon
to mediate the worse clinical behaviour of late stage LSCC with
11q13 amplification.
A role for multiple genes in the biology of 11q13.3
amplification
To evaluate the significance of 11q13.3 amplification it is
imperative to discern the genes selected upon by amplification
based overexpression (‘drivers’) from those whose overexpression
is apparent, yet unrelated to tumour progression (‘hitchhikers’).
Gene by gene functional analyses have revealed that cyclin D1
(Opitz et al, 2001; Nelsen et al, 2005), FADD (Alappat et al, 2003;
Chen et al, 2005) and cortactin (van Rossum et al, 2003; Luo et al,
2006) are potentially able to enhance cancer development.
However, these studies do not account for the effect of multiple
genes located within the 11q13.3 amplicon. By revealing a
relationship to prognosis, we show that cortactin is a potential
driver, independent of cyclin D1 and FADD. Cyclin D1 and FADD
were not significantly related to short DSM in a multivariate Cox
regression model in the present study. However, our present study
contains mainly high T-stage tumour and the univariate sig-
nificance of cyclin D1 and FADD implies a link to amplification.
The 11q13.3 amplicon is 1.7Mb in size and contains 13 genes in
almost all HNSCC cases with 11q13.3 amplification (Gibcus et al,
2007b). Therefore, multiple genes are enabled to increase their
copy number and expression by 11q13.3 amplification (Freier et al,
2006; Gibcus et al, 2007a). Considering the different functions of
cortactin, cyclin D1 and FADD it would be interesting to see
whether these genes, coamplified in the same tumour, have a
function at specific stages of tumorigenesis. Increased expression
of cyclin D1 is detected at early stages of tumorigenesis and found
prior to amplification (Izzo et al, 1998). Interestingly, cyclin D1
overexpression enhances cell division and results in genomic
instability (Nelsen et al, 2005). On the other hand, cortactin
Table 3 Univariate Cox regression for FADD, CCND1and CTTN to
DSM
Cox regression
Hazard ratio for DSM
univariate N (%) HR 95% CI
CCND1 106
Low (o23%) 52 (49) 1
High (423%) 54 (51) 3.51 1.27–9.70 (P¼0.016)
FADD 106
Low ( /+) 60 (57) 1
High (++/+++) 46 (43) 4.73 1.71–13.08 (P¼0.003)
CTTN 106
Low (o13%) 55 (52) 1
High (413%) 51 (48) 13.14 3.04–56.87 (P¼0.0006)
Lymph nodes 106
Negative (cN ) 67 (63) 1
Positive (cN+) 39 (37) 3.16 1.29–7.75 (P¼0.012)
Treatment 106
Surgery 42 (40) 1
Radiotherapy 16 (15) 4.49 1.51–13.41 (P¼0.007)
Both 48 (45) 1.32 0.44–3.94 (P¼0.62)
Abbreviations: CI¼confidence interval; DSM¼disease specific mortality; HR¼
hazard ratio; N pos.¼number of positive cases. Age, gender, T-status and grade
were not significant and not included in this table.
Table 4A Multivariate Cox regression for CCND1, CTTN, FADD and
lymph node metastasis to DSM
Cox regression
Hazard ratio for DSM
multivariate N (%) HR 95% CI
CCND1 106
Low (o23%) 52 (49) 1
High (423%) 54 (51) 1.28 0.38–4.24 (P¼0.69)
FADD 106
Low ( /+) 60 (57) 1
High (++/+++) 46 (43) 1.96 0.57–6.68 (P¼0.29)
CTTN 106
Low (o13%) 55 (52) 1
High (413%) 51 (48) 8.46 1.63–43.88 (P¼0.011)
Lymph nodes 106
Negative (cN ) 67 (63) 1
Positive (cN+) 39 (37) 3.96 1.30–12.06 (P¼0.015)
Treatment 106
Surgery 42 (40) 1
Radiotherapy 16 (15) 2.72 0.75–9.86 (P¼0.13)
Both 48 (45) 0.75 1.50–13.31 (P¼0.67)
Abbreviations: CI¼confidence interval; DSM¼disease specific mortality; HR¼
hazard ratio; N pos.¼number of positive cases.
Table 4B Multivariate Cox regression for CTTN and lymph node
metastasis to DSM
Cox regression
Hazard ratio for DSM
multivariate N (%) HR 95% CI
CTTN 106
Low (o13%) 55 (52) 1
High (413%) 51 (48) 15.96 3.55–71.73 (P¼0.0003)
Lymph nodes 106
Negative (cN ) 67 (63) 1
Positive (cN+) 39 (37) 4.03 1.57–10.35 (P¼0.004)
Abbreviations: CI¼confidence interval; DSM¼disease specific mortality; HR¼
hazard ratio; N pos.¼number of positive cases.
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affecting later stages of cancer development (this study).
Furthermore, cortactin overexpression was reported to inhibit
the ubiquitination-mediated degradation of the epidermal
growth factor receptor, resulting in a sustained ligand-induced
epidermal growth factor receptor activity (van Rossum et al, 2005).
Overexpression promoted resistance to the EGFR kinase inhibitor
gefitinib (Timpson et al, 2007) indicating that cortactin not
only affects invasive but also therapeutic responsive properties of
HNSCC cancers. Finally, FADD expression and phosphorylation
have been shown to affect cell cycle progression (Alappat et al,
2003) and resistance to chemotherapy (Shimada et al, 2004).
Moreover, treatment with combinations of chemotherapy
and radiation (Forastiere et al, 2003; Vermorken et al, 2007)
might be affected by FADD expression due to 11q13 amplifica-
tion, as hypothesized previously (Gibcus et al, 2007b). Because
amplification was proven an early event in tumorigenesis
(Izzo et al, 1998; Burnworth et al, 2006), and amplicons are
inherited during tumorigenesis, we hypothesize that the high
occurrence of 11q13.3 amplification enables multiple genes to be
beneficial to tumour progression at distinct stages of tumour
development.
In summary, our data indicate that cortactin is a good predictor
for disease-related mortality in late stage LSCC. Furthermore,
within lymph node positive tumours, cortactin expression can be
used to distinguish between a good and a bad prognosis.
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Figure 2 Kaplan–Meier analysis on disease-specific mortality for cortactin (A), lymph node positivity (B) and cortactin positivity within lymph node-
positive cases (C). Remaining cases are shown below the plots.
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